GenSight Biologics S.A.: GenSight Biologics Reports Interim

Ramp up of sales marketing actions and investments to drive commercial launch of LUMEVOQ in Europe in 2023 Cash runway confirmed to early Q1 2023 Advanced discussions on refinancing

Related Keywords

Germany , Italy , United Kingdom , France , Spain , Clothilde Caillet , James Palmer , Gensight Biologics Euronext , Gensight Biologics , Thomas Gidoin , Guillaume Van Renterghem , Jeanene Timberlake , Corporate Communications , Sight Biologics , Chief Financial Officer , Year Financial Results , Temporary Authorization , French National Drug Safety Agency , Agence Nationale , Good Manufacturing Practices , Marketing Authorisation Application , Marketing Authorisation , Kreos Bond , Sight Biologic , Mitochondrial Targeting Sequence , Leber Hereditary Optic Neuropathy , Gensight Biologic , Communications Director , Gensight , Iologics , Reports , Interim , Financial , Results , First , Calf , 022 ,